Levamisole

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 30.09.2022

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

immunomodulator (imidazothiazole), which is also used in tumor therapy in combination with fluorouracil. Originally developed as a parasitic agent used in veterinary medicine against worm infestation.

IndicationThis section has been translated automatically.

In combination with fluorouracil for adjuvant therapy in patients with colon carcinoma after surgical removal of the affected colon sections. Also used as combination therapy for malignant melanoma.

Undesirable effectsThis section has been translated automatically.

Exanthema, nervousness, sleep disturbances, depression, nausea, vomiting, loss of appetite, diarrhea, constipation, stomatitis; altered perception of taste, flu-like symptoms, thrombocytopenia; agranulocytosis, myalgia or athralgia, encephalopathy-like syndromes, neurologic abnormalities, multifocal leukoencephalopathy or demyelinating processes; elevation of triglycerides and cholesterol.

ContraindicationThis section has been translated automatically.

Severe liver and kidney dysfunction. Less than 4,000 leukocytes/μl or 120,000 thrombocytes/μl.

PreparationsThis section has been translated automatically.

Ergamisol, Ascaradil (available through the international pharmacy)

Authors

Last updated on: 30.09.2022